Dr. Kulak leads Corporate Strategy and Business Development at Solid Biosciences, having previously held the same role at AavantiBio.
Prior to joining AavantiBio, Dr. Kulak headed strategy at Lonza Biosciences and prior to that, oversaw gene therapy and European business development efforts at BioMarin Pharmaceuticals. Dr. Kulak is especially passionate about rare disease therapies for children. Shuli serves as a member of the Massachusetts General Hospital Rare Disease Think Tank and is a Venture Partner at Deep Science Ventures.
Dr. Kulak earned a medical degree with a distinction in research from Albert Einstein College of Medicine, after which she simultaneously completed an MBA at Sy Syms School of Business and her medical training in Pediatrics.